AGIO catalyst calendar

AGIOS PHARMACEUTICALS, INC.

Upcoming catalysts
7
Cash runway
15.6 months
Cash & investments
$618M
Phase 3 programs
12

AGIOS PHARMACEUTICALS, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on October 29, 2026, a projected date rather than a confirmed one. There are 7 upcoming events on record.

Cash runway is approximately 15.6 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 35 concluded trials, 89% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 29, 2026 est. Next quarterly earnings (projected) Earnings —
January 17, 2028 A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria Trial Milestone Phase 1
March 15, 2029 A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia Trial Milestone Phase 3
June 15, 2029 A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) Trial Milestone Phase 3
August 15, 2029 A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD) Trial Milestone Phase 3
August 15, 2029 A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study Trial Milestone Phase 4
August 15, 2030 A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera Trial Milestone Phase 2/Phase 3

Track AGIO alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open AGIO in the tracker

Recent history

DateEventTypePhase
July 30, 2026 Quarterly results filed (8-K) Earnings —
June 18, 2026 8-K filed: Leadership change Corporate —
May 12, 2026 A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD) Trial Milestone Phase 2
April 29, 2026 Quarterly results filed (8-K) Earnings —
March 17, 2026 A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) Trial Milestone Phase 2
February 12, 2026 Quarterly results filed (8-K) Earnings —
February 11, 2026 A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants Trial Milestone Phase 1
January 12, 2026 8-K filed: Reg FD disclosure Filing —
October 30, 2025 Quarterly results filed (8-K) Earnings —
October 30, 2025 A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP) Trial Milestone Phase 2/Phase 3
October 9, 2025 Single and Multiple Ascending Dose Study and Food Effect Study for AG181 Trial Milestone Phase 1
August 4, 2025 8-K filed: Reg FD disclosure Filing —
July 31, 2025 Quarterly results filed (8-K) Earnings —
July 8, 2025 8-K filed: Leadership change Corporate —
June 18, 2025 8-K filed: Leadership change Corporate —
May 1, 2025 Quarterly results filed (8-K) Earnings —
February 21, 2025 A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy Participants Trial Milestone Phase 1
December 13, 2024 A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period Trial Milestone Phase 3
December 3, 2024 Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants Trial Milestone Phase 1
July 3, 2024 Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007 Trial Milestone Phase 3
May 3, 2024 A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period Trial Milestone Phase 3
April 11, 2024 A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) Trial Milestone Phase 3
December 19, 2023 A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease Trial Milestone Phase 1
November 13, 2023 A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT) Trial Milestone Phase 3
July 21, 2023 A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function Trial Milestone Phase 1
March 19, 2021 A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants Trial Milestone Phase 1
December 3, 2020 A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy Participants Trial Milestone Phase 1
November 23, 2020 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult Participants Trial Milestone Phase 1
November 12, 2020 A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD) Trial Milestone Phase 3
October 9, 2020 A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD) Trial Milestone Phase 3

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.